US4820690A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Duodenal and gastric ulcer treatment with oral urogastrone
Assignee: GD Searle LLC
•
Filing: 1987-07-02
•
Granted: 1989-04-11
•
Expires: 2007-07-02
Abstract
Abstract Pharmaceutical compositions for oral administration comprise human urogastrone or a urogastrone fragment as active ingredient and such an active ingredient may be used for the manufacture of a medicament for promoting healing of a damaged alimentary tract.
Inventors
- 👤 Harold Gregory
- 👤 Keith G. McCullagh
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 23:56
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1808; A61P; A61P1/00; A61P1/04
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
117 words
A method of promoting the healing of duodenal and gastric ulcers in a mammal without inhibiting gastric acid secretion which comprises orally administering to said mammal an amount of beta-urogastrone or a urogastrone fragment selected from the group consisting of a polypeptide comprising amino acids 1-46 of urogastrone, a polypeptide comprising amino acids 1-47 of urogastrone, a polypeptide comprising amino acids 1-48 of urogastrone, a polypeptide comprising amino acids 1-49 of urogastrone, a polypeptide comprising amino acids 1-50 of urogastrone, a polypeptide comprising amino acids 1-51 of urogastrone, a polypeptide comprising amino acids 1-52 of urogastrone; wherein said amount is effective to promote the healing of duodenal and gastric ulcers in mammals without inhibiting gastric acid secretion.
Claim 2
Independent Claim
117 words
A method of promoting the healing of duodenal and gastric ulcers in a mammal without inhibiting gastric acid secretion which comprises orally administering to said mammal an amount of beta-urogastrone or a urogastrone fragment selected from the group consisting of a polypeptide comprising amino acids 1-46 of urogastrone, a polypeptide comprising amino acids 1-47 of urogastrone, a polypeptide comprising amino acids 1-48 of urogastrone, a polypeptide comprising amino acids 1-49 of urogastrone, a polypeptide comprising amino acids 1-50 of urogastrone, a polypeptide comprising amino acids 1-51 of urogastrone, a polypeptide comprising amino acids 1-52 of urogastrone; wherein said amount is effective to promote the healing of duodenal and gastric ulcers in mammals without inhibiting gastric acid secretion.
Claim 3
Dependent Claim
28 words
A method as claimed in claim 1 wherein the beta-urogastrone or urogastrone fragment is orally administered to a mammal having its alimentary tract afflicted with a gastrointestinal ulcer.
Claim 4
Dependent Claim
28 words
A method as claimed in claim 1 wherein the beta-urogastrone or urogastrone fragment is orally administered to a mammal having its alimentary tract afflicted with a duodenal ulcer.
Claim 5
Dependent Claim
24 words
A method as claimed in claim 1 wherein between 0.1 and 100 μg./kg./day of beta-urogastrone or a urogastrone fragment is administered to said mammal.
Claim 6
Dependent Claim
15 words
A method as claimed in claim 1 wherein human beta-urogastrone is administered to said mammal.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-04-10 | 1992-10-10 | 1993-04-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-04-10 | 1996-10-10 | 1997-04-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-04-10 | 2000-10-10 | 2001-04-11 | $7700.00 | Window Closed / Lapsed |